文献速递慢性肾脏病

脂联素受体激动剂AdipoRon改善2型糖尿病模型中的糖尿病肾病

The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes.
PubMed 文献 · J Am Soc Nephrol · 2018-01-12

研究检测27例2型糖尿病患者肾脏中脂联素受体及相关通路表达,并在db/db小鼠、肾小球内皮细胞和足细胞中评估口服AdipoRon的效应。结果显示AdipoRon经肾内AdipoR1/R2激活CaMKKβ/LKB1-AMPK/PPARα通路,减轻氧化应激与凋亡,改善糖尿病肾病。

要点

  • 早期人糖尿病肾病肾小球AdipoR1、AdipoR2、CaMKKβ及磷酸化LKB1、AMPK阳性细胞显著减少
  • AdipoRon经CaMKKβ/磷酸化Ser431LKB1/磷酸化Thr172AMPK/PPARα通路发挥肾脏保护
  • AdipoRon减轻高糖所致肾小球内皮细胞和足细胞氧化应激、凋亡及内皮功能障碍

核心结论

  • AdipoRon通过激活肾内Ca2+/LKB1-AMPK/PPARα通路改善肾小球内皮细胞和足细胞损伤,提示可用于治疗2型糖尿病相关糖尿病肾病。

研究设计与样本

  • 研究纳入27例2型糖尿病患者评估AdipoRs及相关通路表达,并在雄性C57BLKS/J db/db小鼠、肾小球内皮细胞和足细胞中观察AdipoRon效应。

主要发现

  • 人肾脏 glomerulosclerosis 和 tubulointerstitial fibrosis 的程度与肾功能恶化相关。
  • 早期人糖尿病肾病肾小球中AdipoR1、AdipoR2、CaMKKβ表达及磷酸化LKB1、AMPK阳性细胞数显著减少。
  • AdipoRon治疗恢复db/db小鼠糖尿病所致肾脏改变。
  • AdipoRon直接激活肾内AdipoR1和AdipoR2,增加CaMKKβ、磷酸化Ser431LKB1、磷酸化Thr172AMPK和PPARα表达。
  • AdipoRon改善糖尿病所致肾脏氧化应激并抑制凋亡,改善脂质蓄积和内皮功能障碍相关通路。

关键数值与推荐

  • 在高糖处理的人肾小球内皮细胞和鼠足细胞中,AdipoRon增加细胞内Ca2+水平,激活CaMKKβ/磷酸化Ser431LKB1/磷酸化Thr172AMPK/PPARα通路及下游信号。

临床怎么用

  • AdipoRon作为口服活性合成脂联素受体激动剂,可能通过肾脏局部AdipoR-AMPK-PPARα通路用于2型糖尿病相关糖尿病肾病的治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adiponectin exerts renoprotective effects against diabetic nephropathy (DN) by activating the AMP-activated protein kinase (AMPK)/peroxisome proliferative-activated receptor-α (PPARα) pathway through adiponectin receptors (AdipoRs). AdipoRon is an orally active synthetic adiponectin receptor agonist. We investigated the expression of AdipoRs and the associated intracellular pathways in 27 patients with type 2 diabetes and examined the effects of AdipoRon on DN development in male C57BLKS/J db/db mice, glomerular endothelial cells (GECs), and podocytes. The extent of glomerulosclerosis and tubulointerstitial fibrosis correlated with renal function deterioration in human kidneys. Expression of AdipoR1, AdipoR2, and Ca2+/calmodulin-dependent protein kinase kinase-β (CaMKKβ) and numbers of phosphorylated liver kinase B1 (LKB1)- and AMPK-positive cells significantly decreased in the glomeruli of early stage human DN. AdipoRon treatment restored diabetes-induced renal alterations in db/db mice. AdipoRon exerted renoprotective effects by directly activating intrarenal AdipoR1 and AdipoR2, which increased CaMKKβ, phosphorylated Ser431LKB1, phosphorylated Thr172AMPK, and PPARα expression independently of the systemic effects of adiponectin. AdipoRon-induced improvement in diabetes-induced oxidative stress and inhibition of apoptosis in the kidneys ameliorated relevant intracellular pathways associated with lipid accumulation and endothelial dysfunction. In high-glucose-treated human GECs and murine podocytes, AdipoRon increased intracellular Ca2+ levels that activated a CaMKKβ/phosphorylated Ser431LKB1/phosphorylated Thr172AMPK/PPARα pathway and downstream signaling, thus decreasing high-glucose-induced oxidative stress and apoptosis and improving endothelial dysfunction. AdipoRon further produced cardioprotective effects through the same pathway demonstrated in the kidney. Our results show that AdipoRon ameliorates GEC and podocyte injury by activating the intracellular Ca2+/LKB1-AMPK/PPARα pathway, suggesting its efficacy for treating type 2 diabetes-associated DN.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Kim Y, Lim JH, Kim MY, et al. The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes. J Am Soc Nephrol. 2018. PMID: 29330340. doi:10.1681/ASN.2017060627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。